Diabetes and Gout: Causes, Symptoms, and Prevention

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Always consult your physician or a qualified healthcare provider regarding any medical condition or treatment.

Key Takeaways

  • Diabetes and gout are bidirectionally linked through insulin resistance — hyperinsulinemia reduces renal excretion of uric acid, raising serum levels and gout flare risk.
  • About 10 percent of people with type 2 diabetes have gout, compared with about 4 percent of the general adult population.
  • Diabetes medications matter — thiazide and loop diuretics raise uric acid; SGLT2 inhibitors actually lower uric acid; pioglitazone is neutral; metformin and GLP-1 receptor agonists are neutral or favorable.
  • Acute gout flares are treated with colchicine, NSAIDs (cautiously in kidney disease), or oral steroids; chronic urate-lowering therapy aims for serum urate below 6 mg/dL using allopurinol, febuxostat, or probenecid.
  • Diet changes — limiting organ meats, shellfish, beer, sugar-sweetened beverages, and high-fructose foods — and weight loss measurably lower uric acid and flare frequency.

Diabetes and gout share insulin resistance as a common biological driver. Hyperinsulinemia in type 2 diabetes reduces kidney excretion of uric acid, raising serum levels and increasing gout flare risk. Prevalence of gout in type 2 diabetes is around 10 percent, more than double the general adult rate. Treatment combines acute flare management (colchicine, NSAIDs, steroids), chronic urate-lowering therapy (allopurinol, febuxostat) targeting serum urate below 6 mg/dL, diet changes (less beer, organ meat, fructose; more low-fat dairy and coffee), weight loss, and selection of diabetes drugs that lower or are neutral on uric acid (SGLT2 inhibitors, metformin, GLP-1 receptor agonists).

The Insulin Resistance Connection

  • Insulin acts on the kidney’s proximal tubule to increase uric acid reabsorption
  • Hyperinsulinemia therefore reduces uric acid excretion, raising serum levels
  • Fructose metabolism in the liver consumes ATP and generates uric acid
  • Obesity increases both insulin resistance and dietary purine load
  • Lactic acidosis (occasional in metformin users) competes with uric acid for excretion
  • Chronic kidney disease impairs uric acid clearance — common comorbidity in both gout and diabetes

Prevalence and Risk

Population Approximate Gout Prevalence
General adult population (US) 3 to 4 percent
Type 2 diabetes 9 to 11 percent
Metabolic syndrome About 12 to 15 percent
Severe obesity (BMI ≥40) About 15 to 20 percent
Chronic kidney disease stage 3+ 20 to 30 percent

Symptoms of a Gout Attack

  • Sudden onset, often overnight or in early morning
  • Severe pain in one joint — most commonly the first metatarsophalangeal joint (big toe)
  • Other common joints: midfoot, ankle, knee, wrist, finger, elbow
  • Redness, warmth, and swelling
  • Skin over the joint may peel as the flare resolves
  • Tophi (chalky white deposits) under the skin in long-standing disease
  • Low-grade fever sometimes
  • Untreated flares last 7 to 14 days; treated flares resolve in 3 to 5 days

Diagnosis

  • Joint fluid analysis with polarized microscopy is the gold standard — needle-shaped, negatively birefringent monosodium urate crystals
  • Clinical diagnosis often acceptable when classic presentation in big toe, with elevated serum urate, in a high-risk patient
  • Serum urate may be normal during an acute attack — recheck after flare resolves
  • Imaging: ultrasound for “double contour sign”, dual-energy CT for urate deposits, X-ray for chronic changes
  • Differential includes septic arthritis (always rule out — can coexist), pseudogout (calcium pyrophosphate), cellulitis, trauma

Acute Flare Treatment

Treatment Typical Use Cautions
Colchicine 1.2 mg at flare onset, then 0.6 mg 1 hr later; then 0.6 mg once or twice daily Dose-reduce in renal impairment; nausea/diarrhea common; drug interactions with statins, macrolides
NSAIDs (naproxen, indomethacin, ibuprofen) Full anti-inflammatory dose for 5 to 7 days Avoid with CKD stage 3+, heart failure, GI bleeding history; use with caution with ACE inhibitors
Oral prednisone 30 to 40 mg daily for 5 days then taper Hyperglycemia in diabetes — anticipate insulin or medication adjustment
Intra-articular steroid Single joint injection Useful when only one joint involved and septic arthritis ruled out
IL-1 inhibitors (anakinra, canakinumab) Refractory cases when all above contraindicated Expensive; usually rheumatology-supervised

Long-Term Urate-Lowering Therapy

Indications (ACR 2020)

  • Two or more flares per year
  • Tophi present
  • Radiographic damage from gout
  • Chronic kidney disease stage 3+
  • History of kidney stones
  • Serum urate above 9 mg/dL (some guidelines)

Treat-to-Target

  • Goal serum urate below 6 mg/dL
  • Below 5 mg/dL for tophaceous disease or frequent flares
  • Recheck urate every 2 to 5 weeks during titration; every 6 to 12 months once stable
  • Anti-inflammatory prophylaxis (low-dose colchicine 0.6 mg daily or NSAID) for first 3 to 6 months to prevent flares as urate drops

Urate-Lowering Drugs

Drug Mechanism Notes
Allopurinol Xanthine oxidase inhibitor First-line; start 100 mg daily (50 mg in CKD), titrate to urate target; max 800 mg; HLA-B*5801 screening in Asian populations to reduce SCAR risk
Febuxostat (Uloric) Xanthine oxidase inhibitor Second-line; CARES trial showed higher CV mortality vs allopurinol — use cautiously in CV disease
Probenecid Uricosuric (increases excretion) Requires good renal function (CrCl > 50); avoid with kidney stones
Pegloticase (Krystexxa) Recombinant uricase, IV infusion Refractory tophaceous gout only; specialist-administered
Lesinurad Uricosuric (adjunct) Used with xanthine oxidase inhibitor; renal toxicity warning

Diabetes Medications and Uric Acid

Drug Class Effect on Uric Acid
SGLT2 inhibitors Lower uric acid; lower gout flare risk
Metformin Neutral or slightly favorable
GLP-1 receptor agonists Neutral; weight loss may help
DPP-4 inhibitors Neutral
Insulin Neutral; weight gain may raise uric acid indirectly
Pioglitazone Neutral or slightly favorable
Sulfonylureas Neutral

Other Medications That Affect Uric Acid

  • Thiazide diuretics (hydrochlorothiazide, chlorthalidone) — raise uric acid; consider switch if frequent flares
  • Loop diuretics (furosemide, torsemide) — raise uric acid
  • Low-dose aspirin (≤300 mg) — raises uric acid (do not stop if needed for CV protection)
  • Cyclosporine, tacrolimus — raise uric acid significantly
  • Niacin — raises uric acid
  • Losartan (an ARB) — uniquely uricosuric among ARBs; preferred when ARB needed in gout
  • Fenofibrate — lowers uric acid
  • Atorvastatin and rosuvastatin — modestly lower uric acid

Diet and Lifestyle

Foods to Limit

  • Organ meats (liver, kidney, sweetbreads, tripe)
  • Game meats (venison, rabbit, duck)
  • Some seafood (anchovies, sardines, mussels, scallops, mackerel, herring)
  • Red meat in large portions
  • Beer (very strong link)
  • Spirits
  • Sugar-sweetened beverages (soda, fruit juice)
  • High-fructose corn syrup foods

Foods That Help

  • Low-fat dairy (yogurt, milk, cottage cheese) — strongest protective association
  • Coffee (4+ cups daily linked with lower gout risk)
  • Cherries and cherry juice (modest evidence)
  • Vitamin C (500 mg daily — modest lowering)
  • Plant-based proteins (legumes, tofu)
  • Whole grains
  • Vegetables and fruits low in fructose
  • Adequate water intake (target urine output ≥2 L/day if kidney stones)

Weight Loss

  • Sustained 10 percent weight loss lowers uric acid by approximately 1 mg/dL
  • Avoid rapid weight loss or fasting — can transiently raise uric acid and trigger flares
  • Bariatric surgery often initially worsens gout but lowers long-term flare frequency

Comorbidities to Manage

  • Hypertension — common; choose losartan or amlodipine if possible; avoid thiazides if gout is frequent
  • Chronic kidney disease — adjust gout drug doses; SGLT2 inhibitors and ACE inhibitors/ARBs protect kidney function
  • Cardiovascular disease — hyperuricemia is an independent CV risk marker; aggressive lipid and BP control
  • Obstructive sleep apnea — independently raises uric acid through hypoxia
  • Heart failure — diuretic use complicates; tailor regimen with cardiology

When to See a Rheumatologist

  • Diagnostic uncertainty
  • Refractory disease despite urate-lowering therapy at maximum tolerated doses
  • Tophi or joint damage
  • Suspected pseudogout, septic arthritis, or other inflammatory arthritis
  • Severe drug reaction to allopurinol or febuxostat
  • Need for pegloticase (refractory tophaceous gout)

See our overviews on complications and related conditions and diabetes treatment options. The American College of Rheumatology 2020 gout guideline outlines treat-to-target urate-lowering therapy.

The Bottom Line

Diabetes and gout are linked through insulin resistance — hyperinsulinemia reduces kidney excretion of uric acid, raising serum levels and crystal formation in joints. About 10 percent of people with type 2 diabetes have gout. Acute flares are treated with colchicine, NSAIDs, or steroids within 24 hours. Long-term management uses allopurinol (first line) or febuxostat to target serum urate below 6 mg/dL. SGLT2 inhibitors are a smart diabetes drug choice because they lower uric acid; thiazide diuretics worsen it. Diet changes — less beer, organ meat, and fructose; more low-fat dairy, coffee, and water — and 10 percent weight loss measurably reduce flares. Talk to your doctor about a coordinated plan that addresses both conditions together.

Frequently Asked Questions

Why are diabetes and gout linked?

The shared mechanism is insulin resistance and hyperinsulinemia. High insulin levels in type 2 diabetes and prediabetes reduce kidney excretion of uric acid, allowing serum levels to rise. Higher uric acid then crystallizes in joints (most commonly the big toe), causing painful attacks. Gout itself also predicts higher diabetes risk — the relationship is bidirectional. Shared lifestyle drivers (obesity, high-purine and high-fructose diet, alcohol) reinforce both conditions.

Can SGLT2 inhibitors help gout?

Yes. SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin) cause increased urinary excretion of uric acid as a side effect of glucose excretion. Trial data show lower gout flare rates on SGLT2 inhibitors compared with DPP-4 inhibitors or sulfonylureas. For a patient with type 2 diabetes and gout, an SGLT2 inhibitor is often a good choice when otherwise appropriate. Discuss with your clinician.

How is an acute gout flare treated?

Acute flares need rapid anti-inflammatory treatment within the first 24 hours. Options include colchicine (often 1.2 mg now plus 0.6 mg one hour later, then maintenance), NSAIDs (naproxen, ibuprofen, indomethacin — used cautiously in kidney disease or heart failure), or oral steroids (prednisone 30 to 40 mg daily for 5 days). Joint aspiration with steroid injection is an option for a single joint. Apply ice and rest the joint. Continue any chronic urate-lowering therapy through the flare.

What foods raise uric acid?

Foods highest in purines include organ meats (liver, kidney, sweetbreads), some shellfish (anchovies, sardines, mussels, scallops), and game meats. Beer is especially uric-acid raising; spirits and wine to a lesser extent. High-fructose corn syrup (soda, fruit juice, sweets) raises uric acid through metabolism. Sweetened beverages have the strongest dietary link to gout in studies. Favored foods include low-fat dairy, coffee, cherries, whole grains, vegetables, and nuts. Vitamin C may modestly lower uric acid.

Sources

  1. FitzGerald JD, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res 2020.
  2. Choi HK, et al. Pathogenesis of Gout. Ann Intern Med 2005.
  3. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care 47(Suppl 1).